Notogen Appoints Gary Margolis as New Chief Executive Officer
Notogen Inc. (“Notogen”), a biotechnology company developing regenerative therapeutics for conditions related to spinal degeneration, orthopedics and sports medicine, is pleased to announce the appointment of Gary Margolis to the role of Chief Executive Officer (CEO), effective November 15, 2018.
Mr. Margolis is an accomplished healthcare, finance and legal executive who most recently served as Managing Director, General Counsel and Chief Compliance Officer of DRI Capital Inc., a global leader in healthcare investing and the original innovator of the healthcare royalty market. Prior to his tenure at DRI Capital, Mr. Margolis was a legal associate at Dewey Ballantine LLP in London, and Simpson Thacher & Bartlett LLP in New York. Mr. Margolis began his legal career at Osler, Hoskin & Harcourt LLP in Toronto and holds a J.D. and a B.Sc. in Human Biology from the University of Toronto.
Mr. Margolis commented, “I am delighted to be joining the Notogen team and look forward to helping the company achieve its fundraising and clinical development objectives. Notogen’s lead product candidate, NTG-101, is a promising molecular therapy, with the potential to be a game-changing treatment for disc degeneration disease.”
Dr. Mark Erwin, DC, PhD, Co-Founder and CSO of Notogen added, “We are excited to have Gary on board and to leverage his life sciences, business and legal expertise in leading Notogen going forward. With our recent peer-reviewed publications and well-designed development program, we believe the company is well-positioned to capitalize on the current market demand for novel biologic therapies that are being developed for large addressable target markets with no viable treatment options. We look forward to Gary helping us advance NTG-101 and our other pre-clinical development programs so that patients can benefit from these novel treatments.”
NTG-101 is a protein-based biologic designed to mediate the progression of spinal disc degeneration disease (DDD) and induce a restorative and regenerative effect. NTG-101 is administered as a single intradiscal injection, containing a combination of recombinant human (rh) transforming growth factor beta 1 (TGF-β1) and connective tissue growth factor (CTGF) proteins plus excipient factors. In preclinical studies, NTG-101 demonstrates robust anti-inflammatory, anti-catabolic and pro-anabolic effects in animal models of DDD.
Notogen is a biotechnology company developing regenerative therapeutics for conditions related to spinal degeneration, orthopedics and sports medicine. Notogen’s lead candidate, NTG-101, is a targeted, non-surgical, non-cellular protein-based biologic for the treatment of disc degeneration disease. The product is in pre-clinical development and is currently undergoing manufacturing. Based on more than 18 years of clinical and laboratory research, this novel therapeutic has the potential to improve the lives of millions of people worldwide who suffer from back and neck pain. For more information, please visit www.notogen.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181120005122/en/